CD4+CD25+ Tregs and NKT cells: regulators regulating regulators

Trends in Immunology

Volumn 27, Issue 7, 2006, Pages 322-327

  Cava, Antonio La ^a   Kaer, Luc Van ^b   Fu Dong Shi, ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; AUTOANTIGEN; CD1D ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIGENICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL CONTACT; CELL INTERACTION; CELL STIMULATION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; ENTERITIS; ENTEROPATHY; EX VIVO STUDY; HUMAN; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IN VITRO SELECTION; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MYASTHENIA GRAVIS; NATURAL KILLER T CELL; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL;

ANIMALS; HUMANS; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 33745486749     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2006.05.003     Document Type: Review

References (70)

1. Nossal G.J. Negative selection of lymphocytes. Cell 76 (1994) 229-239
2. von Boehmer H. Positive selection of lymphocytes. Cell 76 (1994) 219-228
3. Theofilopoulos A.N. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol. Today 16 (1995) 90-98
4. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
5. Taniguchi M., et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21 (2003) 483-513
6. Hori S., et al. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
7. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23 (2005) 877-900
8. Godfrey D.I., et al. NKT cells: what's in a name?. Nat. Rev. Immunol. 4 (2004) 231-237
9. Godfrey D.I., and Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114 (2004) 1379-1388
10. Kronenberg M., and Gapin L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2 (2002) 557-568
11. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2 (2002) 389-400
12. Gumperz J.E., et al. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195 (2002) 625-636
13. Lee P.T., et al. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195 (2002) 637-641
14. Zhou D., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
15. Kinjo Y., et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520-525
16. Mattner J., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525-529
17. Sriram V., et al. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol. 35 (2005) 1692-1701
18. Terabe M., and Berzofsky J.A. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16 (2004) 157-162
19. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198 (2003) 235-247
20. + regulatory T cells in the steady state. J. Exp. Med. 198 (2003) 737-746
21. + regulatory T cells in vivo. J. Exp. Med. 198 (2003) 249-258
22. Klein L., et al. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8886-8891
23. Miyamoto K., et al. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 413 (2001) 531-534
24. Moodycliffe A.M., et al. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1 (2000) 521-525
25. Beaudoin L., et al. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 17 (2002) 725-736
26. Terabe M., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (2000) 515-520
27. Smyth M.J., and Godfrey D.I. NKT cells and tumor immunity-a double-edged sword. Nat. Immunol. 1 (2000) 459-460
28. +T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105 (2005) 735-741
29. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004) 971-979
30. Hammond K.J., and Kronenberg M. Natural killer T cells: natural or unnatural regulators of autoimmunity?. Curr. Opin. Immunol. 15 (2003) 683-689
31. Wagner M.J., et al. A defect in lineage fate decision during fetal thymic invariant NKT cell development may regulate susceptibility to type 1 diabetes. J. Immunol. 174 (2005) 6764-6771
32. Sharif S., et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat. Med. 7 (2001) 1057-1062
33. Wilson S.B., and Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumor immunity. Nat. Rev. Immunol. 3 (2003) 211-222
34. + regulatory T cells?. Eur. J. Immunol. 35 (2005) 1193-1200
35. Artik S., et al. Tolerance to nickel: oral nickel administration induces a high frequency of anergic T cells with persistent suppressor activity. J. Immunol. 167 (2001) 6794-6803
36. + regulatory T cells suppress NKT cell functions. Cancer Res. 63 (2003) 4516-4520
37. +T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10902-10906
38. +T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175 (2005) 7898-7904
39. + invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J. Immunol. 173 (2004) 1043-1050
40. + antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14622-14626
41. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2 (2002) 797-804
42. Cui J., et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278 (1997) 1623-1626
43. Mendiratta S.K., et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6 (1997) 469-477
44. Shi F.-D., et al. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1 (2000) 245-251
45. Ronet C., et al. NKT cells are critical for the initiation of an inflammatory bowel response against Toxoplasma gondii. J. Immunol. 175 (2005) 899-908
46. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201 (2005) 723-735
47. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
48. + regulatory T cell function. J. Exp. Med. 196 (2002) 851-857
49. Papiernik M., et al. Regulatory CD4 T cells: expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol. 10 (1998) 371-378
50. Malek T.R., et al. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17 (2002) 167-178
51. + lymphocyte and dendritic cell mobilization with intermediate doses of recombinant human granulocyte colony-stimulating factor in healthy donors. Stem Cells Dev. 14 (2005) 310-316
52. Terabe M., et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202 (2005) 1627-1633
53. Bonizzi G., and Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004) 280-288
54. + regulatory and natural killer-like T cells on signals leading to NF-κB activation. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4566-4571
55. Elewaut D., et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of Vα14i NKT cells. J. Exp. Med. 197 (2003) 1623-1633
56. Sivakumar V., et al. Differential requirement for Rel/nuclear factor-κB family members in natural killer T cell development. J. Exp. Med. 197 (2003) 1613-1621
57. Stanic A.K., et al. Cutting edge: The ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase Cθ and NF-κB. J. Immunol. 172 (2004) 4667-4671
58. Schmidt-Supprian M., et al. Mature T cells depend on signaling through the IKK complex. Immunity 19 (2003) 377-389
59. Lu L.F., et al. NF-κB-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation. J. Immunol. 175 (2005) 1651-1657
60. Sun Z., et al. PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 404 (2000) 402-407
61. Ruland J., et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure. Cell 104 (2001) 33-42
62. Hara H., et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 18 (2003) 763-775
63. Egawa T., et al. Requirement for CARMA1 in antigen receptor-induced NF-κB activation and lymphocyte proliferation. Curr. Biol. 13 (2003) 1252-1258
64. Newton K., and Dixit V.M. Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes. Curr. Biol. 13 (2003) 1247-1251
65. Jun J.E., et al. Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity 18 (2003) 751-762
66. Wang D., et al. A requirement for CARMA1 in TCR-induced NF-κB activation. Nat. Immunol. 3 (2002) 830-835
67. Ruefli-Brasse A.A., et al. Regulation of NF-κB-dependent lymphocyte activation and development by paracaspase. Science 302 (2003) 1581-1584
68. Ruland J., et al. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 19 (2003) 749-758
69. La Cava A., and Shi F.-D. Natural and adaptive immune cell-based therapies in autoimmunity. Curr. Med. Chem. 13 (2006) 1557-1566
70. + regulatory T cells. Trends Immunol. 25 (2004) 374-380